Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss of 53 cents per share.
First Quarter Highlights
